The phase III TACTI-002 clinical trial (NCT03625323) used Eftilagimod alpha in combination with pembrolizumab as the first-line treatment for advanced tumors and metastatic NSCLC (part A) (19) and as second-line treatment for NSCLC (refractory to PD-1/PD-L1) (part B) and metastatic head and neck cancer (platinum-resistant) (part C) (20). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.